Director/PDMR Shareholding

Alliance Pharma PLC
18 September 2006




For immediate release                                          18 September 2006


                               ALLIANCE PHARMA PLC
                      ('Alliance Pharma' or 'the Company')


                            Director Share Purchase


Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company,
announces that Andrew Smith, A Non-Executive Director of the Company has
acquired 60,000 ordinary shares in the Company at 16p per share bringing his
total holding to 60,000 ordinary, equivalent to 0.04 per cent of the Company's
issued share capital.



For further information:


Alliance Pharma plc                                        + 44 (0) 1249 466966

John Dawson, Chief Executive
Maddy Scott, Finance Director
www.alliancepharma.co.uk

Buchanan Communications                                    + 44 (0) 20 7466 5000

Mark Court/Lisa Baderoon/Rebecca Dietrich


Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed speciality pharmaceutical
company based in Chippenham, Wiltshire, UK. The company has a strong track
record of acquiring the rights to established niche brands and owns, or shares,
the rights to 34 branded pharmaceutical products and continues to explore
opportunities to expand the range.



Alliance Pharma's products are prescribed in the treatment of a wide range of
conditions and include brands used in periodontitis (a serious gum disease), the
prevention of heart disease, in Parkinson's disease, in nutrition, in nasal
infections, in the treatment of dermatological conditions and in childbirth.
Alliance Pharma's sales are mainly prescription driven.  Its products are
distributed to hospitals directly and to UK and International pharmaceutical
wholesalers which service both hospital and retail pharmacies with their
prescription requirements.



Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor for
the induction of labour.



Alliance Pharma joined the AIM market of the London Stock Exchange in December
2003 and trades under the symbol APH.



                      This information is provided by RNS
            The company news service from the London Stock Exchange